Disclaimer:

Disclaimer: The blog posts and comments on this blog and posts on social networks are not investment recommendation, are provided solely for informational purposes, and do not constitute an offer or solicitation to buy or sell any securities. The opinions expressed on the blog are Petar Posledovich's. Petar Posledovich does not guarantee the accuracy of the information presented on this blog and social networks. The information presented is "as is". The blog is stocks analysis and valuation, Bitcoin, Cryptocurrencies, Artificial Intelligence, AI, deep-learning focused. Independent, unbiased AI insights. Petar Vladimirov Posledovich is not liable for any investment losses incurred by reading and interpreting blog posts on this blog and posts on social networks. Conflicts of interest: I may possess some of the securities, currencies or their derivatives mentioned in the blog post and posts on social networks! The blog is property of Wolfteam Ltd. www.wolfteamedge.com Respectfully yours, Petar Posledovich

Monday, October 30, 2023

Resmed Valuation

Resmed Inc, the American multinational medical equipment company is undervalued, according to Wolfteam Ltd.

Resmed produces equipment mainly for sleep apnea and pulmonary diseases. Resmed Inc actively produced ventilators to solve the Covid-19 pandemic. Whereby Resmed Inc market capitalization doubled since march 2000 at its peak, before falling in recent months.

At 4.22 billion USD revenue, growing at 18.02 % with net profit margin of 21.25 % for the calendar year 2022, Resmed Inc's intrinsic value is 32 billion USD, compared with Resmed Inc's current market capitalization of 19.81 billion USD.

With the global warming the market for equipment for pulmonary diseases is bound to grow faster than previously and thus Resmed Inc's revenue and profitability growth are undervalued, according to Wolfteam Ltd. In addition, the stressful lives we live will make the sleep deprivation problems we experience more acute.

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)